{
    "paper_id": "2197c5fc869ae8d0265b4a6f42aba74975c461c4",
    "metadata": {
        "title": "Journal Pre-proofs Purposing Saikosaponins for the treatment of COVID-19 Purposing Saikosaponins for the treatment of COVID-19",
        "authors": [
            {
                "first": "Eshak",
                "middle": [
                    "I"
                ],
                "last": "Bahbah",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Al-Azhar University",
                    "location": {
                        "settlement": "Damietta",
                        "country": "Egypt"
                    }
                },
                "email": ""
            },
            {
                "first": "Ahmed",
                "middle": [],
                "last": "Negida",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Portsmouth",
                    "location": {
                        "country": "UK"
                    }
                },
                "email": ""
            },
            {
                "first": "Mohamed",
                "middle": [
                    "Salah"
                ],
                "last": "Nabet",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Mohamed",
                "middle": [],
                "last": "Salah",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Zagazig University",
                    "location": {
                        "settlement": "Sharkia",
                        "country": "Egypt"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "Till the moment, there are no approved antiviral treatments for COVID-19. Saikosaponin A, Saikosaponin B, and Saikosaponin D are major triterpenoid saponins derived from Bupleurum falcatum L. (Umbelliferae) with valuable pharmacological activities. These active components exbibit several immunomodulatory, anti-inflammatory, anti-bacterial, antiviral, and anticancer effects. We propose that Saikosaponins might hold the promise for the treatment of COVID-19 based on the following rationale: ",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Saikosaponin B demonstrated in-vitro antiviral activity against HCoV-229E by inhibiting the viral attachment to cells in a dose-dependent manner, blocking the viral penetration into cells, and interfering with the early stage of viral replication, such as virus absorption and penetration [3] . Saikosaponin D inhibits the autophagic activity of Enterovirus A71.",
            "cite_spans": [
                {
                    "start": 289,
                    "end": 292,
                    "text": "[3]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "2-Saikosaponins exhibited antiviral activities against several types of viruses in experimental studies. Saikosaponin A inhibited influenza A virus and reduced lung immunopathology."
        },
        {
            "text": "A molecular docking study demonstrated that Saikosaponin A has a high affinity to bind to a target receptor of the SARS-CoV-2, ACE II receptor [4] .",
            "cite_spans": [
                {
                    "start": 143,
                    "end": 146,
                    "text": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "ref_spans": [],
            "section": "3-"
        },
        {
            "text": "In conclusion, we believe that Saikosaponins are candidate treatment for COVID-19 owing to their anti-inflammatory, immunomodulatory, and antiviral activities. We recommend future well-designed randomized controlled trials to evaluate the safety and efficacy of Saikosaponins in patients with COVID-19.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "3-"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "A systematic review of the active saikosaponins and extracts isolated from radix bupleuri and their applications",
            "authors": [
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Pharm Biol",
            "volume": "55",
            "issn": "",
            "pages": "620--655",
            "other_ids": {
                "DOI": [
                    "10.1080/13880209.2016.1262433"
                ]
            }
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Antiviral and immunoregulatory role against PCV2 in vivo of Chinese herbal medicinal ingredients",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "J Vet Res",
            "volume": "61",
            "issn": "",
            "pages": "405--415",
            "other_ids": {
                "DOI": [
                    "10.1515/jvetres-2017-0062"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Discovery of anti-2019-nCoV agents from Chinese patent drugs via docking screening",
            "authors": [
                {
                    "first": "Y-M",
                    "middle": [],
                    "last": "Yan",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Shen",
                    "suffix": ""
                },
                {
                    "first": "Y-K",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "J-J",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Y-X",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.20944/preprints202002.0254.v1"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "A dose-dependently inhibits the production of several inflammatory mediators ROS, TNFa, COX-2, iNOS, and interleukins (IL-6, IL-8, and IL-10) which are responsible for the cytokine storm of severe COVID-19 patients[1]. Saikosaponin D could exhibit an antiproliferative effect in activated T-lymphocyte, in part via suppression of the nucleotidebinding oligomerization domain 2 (NOD2)/NF-\u03baB, NF-AT, and AP-1 MAPK signaling, which plays a role in the severity and mortality of COVID-19[2].",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": [
        {
            "text": "None to declare Acknowledgement None to declare",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conflict of interest"
        },
        {
            "text": "None to declare",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Funding"
        }
    ]
}